

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SEC  
05 SL

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Policy Directions Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 818 CONNECTICUT AVENUE, NW, SUITE 950			
3. Principal Place of Business (if different from line 2) WASHINGTON DC 20006 City: State/zip (or Country)			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
FRANKIE L. TRULL	(202) 776-0071		31747-238
7. Client Name <input type="checkbox"/> Self Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc., members of the sanofi-aventis Group			6. House ID # 32112017

**TYPE OF REPORT** 8. Year 2005 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇔ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input checked="" type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature Frankie L. Trull Date 09/21/2005

Printed Name and Title FRANKIE L. TRULL, PRESIDENT  
Filing #0dbeb9df-4eb6-4292-8406-6108a1f70e93 - Page 1 of 8

0000462432



Registrant Name Policy Directions Inc. Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceu

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Clinical research  
Patient protections  
FDA policies on OTC drugs

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
FRANKIE L. TRULL	
KATHLEEN (KAY) HOLCOMBE	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo Inc. and Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis group.

Signature Frankie L. Trull Date 09/21/2005

Printed Name and Title FRANKIE L. TRULL, PRESIDENT

000462433



Registrant Name Policy Directions Inc. Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceu

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare payment policy  
Medicare drug benefit

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate  
FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
FRANKIE L. TRULL	
KATHLEEN (KAY) HOLCOMBE	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo Inc. and Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis group.

Signature Frankie L. Trull Date 09/21/2005

Printed Name and Title FRANKIE L. TRULL, PRESIDENT

0000462434





SECRETARY OF THE  
05 SEP 29 PM

Government Relations  
for the 21st Century

September 21, 2005

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, D. C. 20515

Re: Aventis  
32112017

Dear Sir:

Please note that we are now filing our Aventis lobbying report under the client name "Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc., members of the sanofi-aventis Group."

Please find attached an Amended Midyear Lobby Report reflecting this change.

By copy of this letter, I am also notifying the Secretary of the Senate of this change.

Sincerely,

Frankie L. Trull  
President

FLT/asm  
Enclosure

cc: Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, D. C. 20510  
Senate Identification No. 31747-238

0000462435

1/18/2011 11:11:12